As of November 9, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Bright Minds Biosciences Inc. The largest reported stake is Ian McDonald's, at 13.7%. 17 filings are on record since August 13, 2025 (Schedule 13D/A, July 2, 2026).
Sell to companies like Bright Minds Biosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Cormorant Asset Management, LP · Sole voting: 0 · Shared voting: 900,000 · Sole dispositive: 0 · Shared dispositive: 900,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Adage Capital Management, L.P. · Sole voting: 0 · Shared voting: 335,000 · Sole dispositive: 0 · Shared dispositive: 335,000 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: Ian McDonald · Sole voting: 1,396,665 · Shared voting: 0 · Sole dispositive: 1,396,665 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-07-02
- · Holder: Vestal Point Capital, LP · Percent: 5% · SCHEDULE 13G
- · Holder: Janus Henderson Group Plc · Percent: 13.1% · SCHEDULE 13G/A
Bright Minds Biosciences Inc. has 17 Schedule 13D or 13G filings on record since 2025-08-13. 5 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 13.7% | 1,396,665 | SCHEDULE 13D/A, 2026-07-02 | 2024-11-04 | |
| Janus Henderson Group Plc | 13.1% | 1,284,324 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Cormorant Asset Management, LP | 9.17% | 900,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Vivo Opportunity Fund Holdings, L.P. | 5.2% | 504,645 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 |
| Vestal Point Capital, LP | 5% | 492,319 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Perceptive Advisors LLC | 4.6% | 449,290 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Adage Capital Management, L.P. | 3.41% | 335,000 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Sio Capital Management, LLC | 2.69% | 190,764 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 |
| Commodore Capital LP | 0.3% | 18,851 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Bright Minds Biosciences Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Bright Minds Biosciences Inc. and the records around it.
Bright Minds Biosciences Inc. elsewhere on the record
Companies that share a holder
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
Watch Bright Minds Biosciences Inc.
Get an email when Bright Minds Biosciences Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bright Minds Biosciences Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Bright Minds Biosciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bright Minds Biosciences Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Ian McDonald | 1,396,665 | 0 | 1,396,665 | 0 | SCHEDULE 13D/A, 2026-07-02 |
| Cormorant Asset Management, LP | 0 | 900,000 | 0 | 900,000 | SCHEDULE 13G/A, 2026-08-14 |
| Bihua Chen | 0 | 900,000 | 0 | 900,000 | SCHEDULE 13G/A, 2026-08-14 |
| Adage Capital Management, L.P. | 0 | 335,000 | 0 | 335,000 | SCHEDULE 13G/A, 2026-08-12 |
| Robert Atchinson | 0 | 335,000 | 0 | 335,000 | SCHEDULE 13G/A, 2026-08-12 |
| Phillip Gross | 0 | 335,000 | 0 | 335,000 | SCHEDULE 13G/A, 2026-08-12 |
The latest filing identifies Bright Minds Biosciences Inc. by CUSIP 10919W405 and gives its principal executive office as 400 N Aberdeen Street, Suite 900, Chicago, IL 60642 (SCHEDULE 13G/A, 2026-08-14).
Source of funds (Item 3)
Not Applicable.Ian McDonald, SCHEDULE 13D/A, 2026-07-02
Purpose of Transaction (Item 4)
Ian McDonald
The purpose of this statement is to report aggregate reductions in ownership of securities held by the Reporting Person of one percent (1%) or more of the securities of the Issuer then outstanding, as a result of distributions of securities by the Issuer, as of: - November 4, 2024, when the Reporting Person had the sole power to vote or to direct the voting of, or to dispose or to direct the disposition of 1,396,665 Common Shares representing approximately 19.0% of the Issuer's issued and outstanding Common Shares inclusive of Common Shares issuable to the Reporting Person pursuant to the Derivative Securities held by the Reporting Person; - September 9, 2025, when the Reporting Person had the sole power to vote or to direct the voting of, or to dispose or to direct the disposition of 1,396,665 Common Shares representing approximately 17.9% of the Issuer's issued and outstanding Common Shares inclusive of Common Shares issuable to the Reporting Person pursuant to the Derivative Securities held by the Reporting Person; and - January 9, 2026, when the Reporting Person had the sole power to vote or to direct the voting of, or to dispose or to direct the disposition of 1,396,665 Common Shares representing approximately 13.8% of the Issuer's issued and outstanding Common Shares inclusive of Common Shares issuable to the Reporting Person pursuant to the Derivative Securities held by the Reporting Person. The Reporting Person may, depending on market and other conditions, increase …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-02; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Sio Capital Management, LLC | 7.27% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 16.3% | SCHEDULE 13G/A |
| 2025-11-12 | Sio Capital Management, LLC | 2.69% | SCHEDULE 13G/A |
| 2025-11-13 | Adage Capital Management, L.P. | 5.58% | SCHEDULE 13G |
| 2025-11-14 | Vivo Opportunity Fund Holdings, L.P. | 6.4% | SCHEDULE 13G |
| 2026-02-06 | Cormorant Asset Management, LP | 10.88% | SCHEDULE 13G/A |
| 2026-02-17 | Perceptive Advisors LLC | 4.6% | SCHEDULE 13G/A |
| 2026-02-17 | Janus Henderson Group Plc | 14.9% | SCHEDULE 13G/A |
| 2026-02-17 | Commodore Capital LP | 0.3% | SCHEDULE 13G/A |
| 2026-04-30 | Cormorant Asset Management, LP | 9.71% | SCHEDULE 13G/A |
| 2026-05-12 | Vivo Opportunity Fund Holdings, L.P. | 5.2% | SCHEDULE 13G/A |
| 2026-05-15 | Vestal Point Capital, LP | 5% | SCHEDULE 13G |
| 2026-05-15 | Janus Henderson Group Plc | 13.1% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 13.1% | SCHEDULE 13G/A |
| 2026-07-02 | Ian McDonald | 13.7% | SCHEDULE 13D/A |
| 2026-08-12 | Adage Capital Management, L.P. | 3.41% | SCHEDULE 13G/A |
| 2026-08-14 | Cormorant Asset Management, LP | 9.17% | SCHEDULE 13G/A |
Questions about who owns Bright Minds Biosciences Inc.
Who owns Bright Minds Biosciences Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Bright Minds Biosciences Inc.: Ian McDonald (13.7%, Schedule 13D/A, filed 2026-07-02), Janus Henderson Group Plc (13.1%, Schedule 13G/A, filed 2026-05-15), Cormorant Asset Management, LP (9.17%, Schedule 13G/A, filed 2026-08-14), Vivo Opportunity Fund Holdings, L.P. (5.2%, Schedule 13G/A, filed 2026-05-12) and Vestal Point Capital, LP (5%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Bright Minds Biosciences Inc.?
By the share each holder's latest filing reports, the largest holders of Bright Minds Biosciences Inc. on this page are Ian McDonald (13.7%), Janus Henderson Group Plc (13.1%) and Cormorant Asset Management, LP (9.17%).
When did Ian McDonald buy into Bright Minds Biosciences Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ian McDonald on this page is the Schedule 13D/A, filed 2026-07-02, reporting 13.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Bright Minds Biosciences Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 19, 2024 | Form D, private offering | $34.60M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Bright Minds Biosciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.